摘要
因Ｂ６６３可致皮肤着色，有些病人每日自服５０毫克很难，遂参照ＷＨＯ方案，将ＭＤＴ改为每月监服ＲＦＰ和Ｂ６６３各１２００毫克，加每日自服ＤＤＳ１００毫克。以此改良的方案于１９８３～１９９６年共治疗１２２例ＭＢ病人，其中６例死亡，２例处迁，完成治疗者为１１４例，包括ＢＴ２、ＢＢ２９、ＢＬ４２及ＬＬ４１；新病人３２、复发者３６，用ＤＤＳ尚未治愈者４６；男１０１，女１３，年龄２２～７０岁，病期１～５４年；查菌均为阳性，ＢＩ０．７～６．０，平均３．４０。８３例ＢＩ≤３．０者，治疗后每年平均下降０．５２；３２例≥３．０者，年均下降０．７；１０１例在１～６年中细菌阴转。治疗３个月皮疹开始消退，１２～１８个月基本消逝。１０１例愈后随访１～１０年，共８７５人年，未见复发。治疗期间只有少数曾发生轻微的药物副作用。
Because of skin coloration,self-taking 50mg B663 a day is very difficult to be regularly taken for some of the patients,and therefore the authors,on the basis of WHO-MDT,have drawn up a modified regimen,consisting of supervised RMP 1200mg and B663 1200mg a month and self-taking DDS 100mg a day.In 1983 to 1996,122 MB cases of leprosy had been treated with the modified MDT,of which six died,two lost and 114 cases completed their course of the treatment including 32 new,36 relapsed and 46 patients who used DDS monotherapy but were still active clinically with age of 22 to 70 years,disease duratlon of one to 54 years and BI of 07 to 60.During the treatment,BI decreased by 052 for those with BI of 30 or less and by 07 for those with BI of over 30. 101 cases became negative by skin smear within one to six years,and the skin lesions began resolving three monghs after treatment and lost basically within 12 to 18 months.There was no relapse in follow-up of one to ten years for the 101 cured persons.
